triazolam has been researched along with Cannabis Abuse in 2 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we present five cases of seizures following withdrawal of flunitrazepam, lorazepam, or triazolam, representing 3% of a sample consisting of 153 patients dependent on benzodiazepines." | 3.69 | Benzodiazepine withdrawal syndrome seizures. ( de Iceta, M; Martínez-Cano, H; Martínez-Gras, I; Pomalima, R; Vela-Bueno, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lile, JA | 1 |
| Kelly, TH | 1 |
| Pinsky, DJ | 1 |
| Hays, LR | 1 |
| Martínez-Cano, H | 1 |
| Vela-Bueno, A | 1 |
| de Iceta, M | 1 |
| Pomalima, R | 1 |
| Martínez-Gras, I | 1 |
2 other studies available for triazolam and Cannabis Abuse
| Article | Year |
|---|---|
Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
Topics: Administration, Oral; Adult; Case-Control Studies; Discrimination, Psychological; Double-Blind Metho | 2009 |
Benzodiazepine withdrawal syndrome seizures.
Topics: Adult; Anti-Anxiety Agents; Female; Flunitrazepam; Heroin Dependence; Humans; Hypnotics and Sedative | 1995 |